175865-60-8

Basic information

• Product Name: Valganciclovir
• Synonyms: valganciclovir;5-amino-3-[1-(hydroxymethyl)-2-(l-valyloxy)ethoxymethyl]-6,7- dihydro-3h-imidazo[4,5-d]pyrimidin-7-one;Valgancyclovir;Valganciclovir & Valganciclovir Hydrochloride;Valganciclovir-d8;(2S)-2-((2-AMino-6-oxo-1H-purin-9(6H)-yl)Methoxy)-3-hydroxypropyl 2-aMino-3-Methylbutanoate;Valganciclovir-d5 HCl (Mixture of diastetroMers);Valganciclovir-d8 (Mixture of Diastereomers)
• CAS NO: 175865-60-8
• Molecular Formula: C14H22N6O5
• Molecular Weight: 354.36168
• EINECS: 1312995-182-4
• Product Categories: API
• Mol File: 175865-60-8.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 629.1 °C at 760 mmHg
• Flash Point: 334.3 °C
• Appearance: /
• Density: 1.59 g/cm³
• Vapor Pressure: 1.08E-16mmHg at 25°C
• Refractive Index: 1.677
• PKA: 9.32±0.20(Predicted)
• CAS DataBase Reference: Valganciclovir(CAS DataBase Reference)
• NIST Chemistry Reference: Valganciclovir(175865-60-8)
• EPA Substance Registry System: Valganciclovir(175865-60-8)

Safety Data

• Hazardous Substances Data: 175865-60-8(Hazardous Substances Data)

Usage

Description

Valganciclovir is a synthetic analogue of 2'-deoxyguanosine and the L-valinyl ester of ganciclovir, which is rapidly converted into ganciclovir by intestinal and hepatic esterases. It is a pro-drug of Ganciclovir, designed to enhance the bioavailability of the active compound.

Uses

Used in Antiviral Applications:
Valganciclovir is used as an antiviral agent for the treatment of various viral infections, particularly those caused by retroviruses. It is effective in managing and preventing the spread of the virus, thus helping to improve the overall health and well-being of the infected individual.
Used in Pharmaceutical Industry:
Valganciclovir is used as an active pharmaceutical ingredient in the development of antiviral medications. Its role in the pharmaceutical industry is crucial, as it helps in the formulation of drugs that target and combat viral infections, contributing to the overall advancement of medical treatments for such conditions.
Used in Research and Development:
Valganciclovir is also used as a labeled analogue (Valganciclovir-d8) in research and development for the study of retro-viruses and their treatment. This labeled analogue aids in understanding the mechanisms of action, pharmacokinetics, and potential drug interactions, further enhancing the knowledge and development of effective antiviral therapies.

Indications

Valganciclovir (Valcyte) is the L-valyl ester prodrug of ganciclovir.

Clinical Use

Oral valganciclovir is comparable to intravenous ganciclovir for the treatment and suppression of CMV retinitis in AIDS patients.

Drug interactions

Potentially hazardous interactions with other drugs Antibacterials: increased risk of convulsions with imipenem-cilastatin. Antivirals: possibly increased didanosine concentration; profound myelosuppression with zidovudine - avoid if possible. Mycophenolate: possibly increased concentrations of both mycophenolic acid and ganciclovir. Increased risk of myelosuppression with other myelosuppressive drugs.

Metabolism

Valganciclovir is well absorbed from the gastrointestinal tract and rapidly and extensively metabolised in the intestinal wall and liver to ganciclovir. Valganciclovir is eliminated in the urine as unchanged ganciclovir, mainly by glomerular filtration and also active tubular secretion.

InChI:InChI=1/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8?,9-/m0/s1